Thousand Oaks-based drug development company Atara Biotherapeutics announced this morning that it has added Matthew K. Fust as a board member, and hired Mitchall G. Clark as its Chief Regulatory and Quality Assurance Officer. Fust was most recently EVP and CFO at Onyx Pharmaceuticals, and als ohas served at Jazz Pharmaceuticals, Perlegen Sciences, and ALZA Corporation. He also serves on the boards of MacroGenics, Sunesis Pharmacueticals, and Ultragenyx Pharmaceuticals. Clark was previously at Nantworks, serving as Senior Vice President, Regulatory Affairs, in addition to serving at Abraxis, American Pharmaceutical Partners, and VivoRX. Atara Biotherapeutics is backed by Alexandria Venture Investments, Amgen Ventures, The Baupost Group, Celgene Corporation, DAG Ventures, Domain Associates, EcoR1 Capital and Kleiner Perkins Caufield & Byers, and raised a big $52M funding round in January.
Top NewsTuesday, April 8, 2014
Atara Biotherapeutics Bolsters Board, Executives